Literature DB >> 20822184

Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as α4β2-nicotinic acetylcholine receptor-selective partial agonists.

Jianhua Liu1, J Brek Eaton, Barbara Caldarone, Ronald J Lukas, Alan P Kozikowski.   

Abstract

In order to advance therapeutic applications of nicotinic ligands, continuing resn class="Chemical">earch efforts are being directed toward the identification and characterization of novel nicotinic acetylcholine receptor (nAChR) ligands that are both potent and subtype selective. Herein we report the synthesis and pharmacological evaluation of members of a new series of 3-alkoxy-5-aminopyridine derivatives that display good selectivity for the α4β2-nAChR subtype based on ligand binding and functional evaluations. The most potent ligand in this series, compound 64, showed high radioligand binding affinity and selectivity for rat α4β2-nAChR with a K(i) value of 1.2 nM and 4700-fold selectivity for α4β2- over α3β4-nAChR, and ∼100-fold selectivity for functional, high-sensitivity, human α4β2-nAChR over α3β4*-nAChR. In the mouse forced swim test, compound 64 exhibited antidepressant-like effects. Structure-activity relationship (SAR) analyses suggest that the introduction of additional substituents to the amino group present on the pyridine ring of the N-demethylated analogue of compound 17 can provide potent α4β2-nAChR-selective ligands for possible use in treatment of neurological and psychiatric disorders including depression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20822184      PMCID: PMC2957884          DOI: 10.1021/jm100765u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  49 in total

1.  Insights for predicting blood-brain barrier penetration of CNS targeted molecules using QSPR approaches.

Authors:  Yi Fan; Rayomand Unwalla; Rajiah A Denny; Li Di; Edward H Kerns; David J Diller; Christine Humblet
Journal:  J Chem Inf Model       Date:  2010-06-28       Impact factor: 4.956

Review 2.  Central nicotinic receptors: structure, function, ligands, and therapeutic potential.

Authors:  M Novella Romanelli; Paola Gratteri; Luca Guandalini; Elisabetta Martini; Claudia Bonaccini; Fulvio Gualtieri
Journal:  ChemMedChem       Date:  2007-06       Impact factor: 3.466

Review 3.  Structural and functional diversity of native brain neuronal nicotinic receptors.

Authors:  Cecilia Gotti; Francesco Clementi; Alice Fornari; Annalisa Gaimarri; Stefania Guiducci; Irene Manfredi; Milena Moretti; Patrizia Pedrazzi; Luca Pucci; Michele Zoli
Journal:  Biochem Pharmacol       Date:  2009-05-27       Impact factor: 5.858

4.  RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization.

Authors:  M Bencherif; M E Lovette; K W Fowler; S Arrington; L Reeves; W S Caldwell; P M Lippiello
Journal:  J Pharmacol Exp Ther       Date:  1996-12       Impact factor: 4.030

5.  Is agonist self-inhibition at the nicotinic acetylcholine receptor a nonspecific action?

Authors:  S A Forman; L L Firestone; K W Miller
Journal:  Biochemistry       Date:  1987-05-19       Impact factor: 3.162

6.  A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.

Authors:  J P Sullivan; D Donnelly-Roberts; C A Briggs; D J Anderson; M Gopalakrishnan; M Piattoni-Kaplan; J E Campbell; D G McKenna; E Molinari; A M Hettinger; D S Garvey; J T Wasicak; M W Holladay; M Williams; S P Arneric
Journal:  Neuropharmacology       Date:  1996-06       Impact factor: 5.250

7.  6'-Methylpyrido[3,4-b]norhomotropane: synthesis and outstanding potency in relation to the alpha4beta2 nicotinic receptor pharmacophore model.

Authors:  David B Kanne; Motohiro Tomizawa; Kathleen A Durkin; John E Casida
Journal:  Bioorg Med Chem Lett       Date:  2005-02-15       Impact factor: 2.823

8.  Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.

Authors:  M Imad Damaj; F Ivy Carroll; J Brek Eaton; Hernan A Navarro; Bruce E Blough; Sadiq Mirza; Ronald J Lukas; Billy R Martin
Journal:  Mol Pharmacol       Date:  2004-09       Impact factor: 4.436

Review 9.  Nicotinic acetylcholine receptors as targets for antidepressants.

Authors:  R D Shytle; A A Silver; R J Lukas; M B Newman; D V Sheehan; P R Sanberg
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

Review 10.  Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.

Authors:  Enrique L M Ochoa; Jose Lasalde-Dominicci
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

View more
  8 in total

1.  Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.

Authors:  Li-Fang Yu; Werner Tückmantel; J Brek Eaton; Barbara Caldarone; Allison Fedolak; Taleen Hanania; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2012-01-04       Impact factor: 7.446

2.  Effects of sazetidine-A, a selective α4β2* nicotinic receptor desensitizing agent, on body temperature regulation in mice and rats.

Authors:  Amir H Rezvani; Olga Timofeeva; Hannah G Sexton; Damien DeCuir; Yingxian Xiao; Christopher J Gordon; Kenneth J Kellar; Edward D Levin
Journal:  Eur J Pharmacol       Date:  2012-02-24       Impact factor: 4.432

3.  The twin drug approach for novel nicotinic acetylcholine receptor ligands.

Authors:  Isabelle Tomassoli; Daniela Gündisch
Journal:  Bioorg Med Chem       Date:  2015-06-20       Impact factor: 3.641

4.  Discovery of isoxazole analogues of sazetidine-A as selective α4β2-nicotinic acetylcholine receptor partial agonists for the treatment of depression.

Authors:  Jianhua Liu; Li-Fang Yu; J Brek Eaton; Barbara Caldarone; Katie Cavino; Christina Ruiz; Matthew Terry; Allison Fedolak; Daguang Wang; Afshin Ghavami; David A Lowe; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2011-09-30       Impact factor: 7.446

5.  Discovery of highly potent and selective α4β2-nicotinic acetylcholine receptor (nAChR) partial agonists containing an isoxazolylpyridine ether scaffold that demonstrate antidepressant-like activity. Part II.

Authors:  Li-Fang Yu; J Brek Eaton; Allison Fedolak; Han-Kun Zhang; Taleen Hanania; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2012-11-02       Impact factor: 7.446

6.  Pd-catalyzed asymmetric β-hydride elimination en route to chiral allenes.

Authors:  Ian T Crouch; Robynne K Neff; Doug E Frantz
Journal:  J Am Chem Soc       Date:  2013-03-19       Impact factor: 15.419

7.  Effects of the sazetidine-a family of compounds on the body temperature in wildtype, nicotinic receptor β2-/- and α7-/- mice.

Authors:  Edward D Levin; Hannah G Sexton; Karen Gordon; Christopher J Gordon; Yingxian Xiao; Kenneth J Kellar; Venkata Mahidhar Yenugonda; Yong Liu; Michael P White; Mikell Paige; Milton L Brown; Amir H Rezvani
Journal:  Eur J Pharmacol       Date:  2013-09-12       Impact factor: 4.432

Review 8.  Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.

Authors:  Li-Fang Yu; Han-Kun Zhang; Barbara J Caldarone; J Brek Eaton; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2014-07-02       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.